

# Aly-Khan A Lalani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7137064/publications.pdf>

Version: 2024-02-01

84  
papers

1,456  
citations

471509

17  
h-index

414414

32  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2735  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Journal of Urology, 2022, 207, 16-24.   | 0.4 | 31        |
| 2  | Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research, 2022, 28, 738-747.        | 7.0 | 11        |
| 3  | Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.   |     | 15        |
| 4  | Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology, 2022, 40, TPS398-TPS398.  | 1.6 | 3         |
| 5  | Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2022, 40, 316-316.              | 1.6 | 1         |
| 6  | Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. Journal of Clinical Oncology, 2022, 40, 304-304.   | 1.6 | 0         |
| 7  | Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2022, 20, 210-218.  | 1.9 | 4         |
| 8  | Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211086.   | 3.2 | 15        |
| 9  | Emerging Biomarker-Guided Therapies in Prostate Cancer. Current Oncology, 2022, 29, 5054-5076.   | 2.2 | 10        |
| 10 | Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma. Canadian Urological Association Journal, 2021, 15, 281-286.  | 0.6 | 7         |
| 11 | Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Kidney Cancer, 2021, 5, 21-29.  | 0.4 | 3         |
| 12 | Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. Soci  t   Internationale D'urologie Journal, 2021, 2, 82-95.  | 0.4 | 0         |
| 13 | Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 773.   | 7.1 | 21        |
| 14 | Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer, 2021, 19, 521-530.  | 1.9 | 8         |
| 15 | Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Canadian Urological Association Journal, 2021, 15, 353-358.   | 0.6 | 2         |
| 16 | The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients. Canadian Urological Association Journal, 2021, 16, .   | 0.6 | 1         |
| 17 | PD40-07  fCLINICAL OUTCOMES AND ADVERSE EVENTS AFTER FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. Journal of Urology, 2021, 206, .  | 0.4 | 1         |
| 18 | Cabozantinib real  world effectiveness in the first  through fourth  line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine, 2021, 10, 1212-1221. | 2.8 | 22        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | The emerging treatment landscape of advanced urothelial carcinoma. Current Opinion in Supportive and Palliative Care, 2021, Publish Ahead of Print, 247-252.   | 1.3 | 1         |
| 20 | Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. Current Oncology, 2021, 28, 226-232.   | 2.2 | 2         |
| 21 | State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus, 2020, 6, 37-40.  | 3.1 | 6         |
| 22 | Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 372-381.  | 5.4 | 59        |
| 23 | From Famine to Feast: Treating Urinary Malignancies in the Immunotherapy Era. European Urology Focus, 2020, 6, 1-2.  | 3.1 | 2         |
| 24 | Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European Urology Oncology, 2020, 3, 695-699.   | 5.4 | 30        |
| 25 | Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From The Canadian Kidney Cancer Information System (CKCis). International Journal of Radiation Oncology Biology Physics, 2020, 108, e887.                              | 0.8 | 0         |
| 26 | 211: Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCIS). Radiotherapy and Oncology, 2020, 150, S89-S90.  | 0.6 | 0         |
| 27 | Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer, 2020, 4, 119-119.  | 0.4 | 0         |
| 28 | Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer, 2020, 135, 203-210.   | 2.8 | 50        |
| 29 | Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology, 2020, 6, 293-306.  | 1.8 | 4         |
| 30 | Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.  | 0.6 | 11        |
| 31 | Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 639-639. | 1.6 | 3         |
| 32 | Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology, 2020, 38, TPS761-TPS761.  | 1.6 | 12        |
| 33 | Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2020, 38, 682-682.   | 1.6 | 2         |
| 34 | Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade. , 2020, , .   |     | 0         |
| 35 | Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2020, 38, 633-633.                 | 1.6 | 0         |
| 36 | Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 642-642.  | 1.6 | 9         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2020, 38, 620-620.  | 1.6  | 1         |
| 38 | Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology, 2019, 30, v396.  | 1.2  | 4         |
| 39 | CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology, 2019, 30, v885.  | 1.2  | 12        |
| 40 | Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.   | 0.6  | 10        |
| 41 | Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology, 2019, 76, 852-860.   | 1.9  | 9         |
| 42 | Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2019, 14, 122-129.  | 0.6  | 3         |
| 43 | A A Canadian consensus forum on the management of patients with advanced prostate cancer. Canadian Urological Association Journal, 2019, 14, E137-E149.  | 0.6  | 15        |
| 44 | Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.   | 12.8 | 139       |
| 45 | Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. Canadian Urological Association Journal, 2019, 14, E154-E158.   | 0.6  | 15        |
| 46 | Capturing recurrence in urothelial carcinoma: â€œmore than meets the eyeâ€•. Translational Andrology and Urology, 2019, 8, S524-S527.  | 1.4  | 0         |
| 47 | Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.                    | 0.6  | 3         |
| 48 | Systemic treatments for metastatic urothelial carcinoma. Expert Opinion on Pharmacotherapy, 2019, 20, 201-208.   | 1.8  | 12        |
| 49 | Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology, 2019, 75, 100-110.   | 1.9  | 178       |
| 50 | Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology, 2019, 37, 4516-4516.   | 1.6  | 6         |
| 51 | Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 566-566.   | 1.6  | 9         |
| 52 | Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2019, 37, 568-568. | 1.6  | 3         |
| 53 | Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer, 2018, 118, 1238-1242.   | 6.4  | 33        |
| 54 | Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research, 2018, 6, 402-408.   | 3.4  | 56        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2018, 13, 166-174. | 0.6  | 10        |
| 56 | Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology, 2018, 29, viii311.   | 1.2  | 9         |
| 57 | Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 2018, 119, 707-712.  | 6.4  | 28        |
| 58 | Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer, 2018, 118, 1434-1441.   | 6.4  | 34        |
| 59 | Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.  |      | 200       |
| 60 | The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-“Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2018, 6, 758-765.   | 3.4  | 89        |
| 61 | Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.   | 0.4  | 10        |
| 62 | JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncology, The, 2018, 19, 5-7.  | 10.7 | 2         |
| 63 | Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 607-607.   | 1.6  | 12        |
| 64 | Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 626-626.  | 1.6  | 1         |
| 65 | CD73 expression in primary and metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, 643-643.  | 1.6  | 1         |
| 66 | Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.   | 1.6  | 0         |
| 67 | Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. Journal of Clinical Oncology, 2018, 36, 629-629.                                  | 1.6  | 0         |
| 68 | Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-“Lymph Node Distant Metastasis. Clinical Genitourinary Cancer, 2017, 15, e1089-e1094.  | 1.9  | 3         |
| 69 | Pan-urolologic cancer genomic subtypes that transcend tissue of origin. Nature Communications, 2017, 8, 199.   | 12.8 | 49        |
| 70 | Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 724-732.   | 1.9  | 34        |
| 71 | Immunotherapy in the Elderly. European Urology Focus, 2017, 3, 403-412.  | 3.1  | 16        |
| 72 | First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal, 2017, 11, 112.   | 0.6  | 32        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.  |     | 37        |
| 74 | Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC). Annals of Oncology, 2017, 28, v314-v315.  | 1.2 | 0         |
| 75 | Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 4573-4573.   | 1.6 | 1         |
| 76 | Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology, 2017, 35, 468-468.       | 1.6 | 4         |
| 77 | Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.   | 1.8 | 19        |
| 78 | Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 493-493.  | 1.6 | 0         |
| 79 | Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology, 2017, 35, e16078-e16078. | 1.6 | 0         |
| 80 | Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2017, 35, e16065-e16065.   | 1.6 | 0         |
| 81 | Outcomes of women with small, early-stage breast cancer in Manitoba from 2006-2011.. Journal of Clinical Oncology, 2017, 35, e12000-e12000.   | 1.6 | 0         |
| 82 | Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology, 2016, 27, vi285.  | 1.2 | 1         |
| 83 | Abstract P3-07-13: Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011. , 2015, , .  |     | 0         |
| 84 | Manifestations of Von Hippel Lindau syndrome: a retrospective national review. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 291-296.  | 0.5 | 10        |